Immunivant
Laufzeit: 01.01.2019 - 31.12.2022
Kurzfassung
A PHASE 2b, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY EVALUATING A NEW MONOCLONAL ANTIBODY TREATMENT IN SUBJECTS WITH ACTIVE THYROID EYE DISEASE
Laufzeit: 01.01.2019 - 31.12.2022
A PHASE 2b, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY EVALUATING A NEW MONOCLONAL ANTIBODY TREATMENT IN SUBJECTS WITH ACTIVE THYROID EYE DISEASE
